3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Carcinoma, Non-Small-Cell Lung
234
Breast Neoplasms
234
Prostatic Neoplasms
172
Multiple Myeloma
154
Neoplasms
135
Colorectal Neoplasms
126
Leukemia, Myeloid, Acute
123
Lung Neoplasms
109
Neoplasm Metastasis
101
Squamous Cell Carcinoma of Head and Neck
94
Carcinoma, Hepatocellular
91
Melanoma
89
Lymphoma
85
Triple Negative Breast Neoplasms
77
Pancreatic Neoplasms
76
Ovarian Neoplasms
72
Sarcoma
71
Brain Neoplasms
66
Lymphoma, Large B-Cell, Diffuse
65
Carcinoma, Renal Cell
65
Recurrence
63
Precursor Cell Lymphoblastic Leukemia-Lymphoma
60
Head and Neck Neoplasms
56
Lymphoma, Non-Hodgkin
55
Leukemia, Lymphocytic, Chronic, B-Cell
55
Stomach Neoplasms
52
Hematologic Neoplasms
52
Endometrial Neoplasms
52
Urinary Bladder Neoplasms
51
Rectal Neoplasms
50
Interventions
mirvetuximab soravtansine
1
liposomal doxorubicin
1
Paclitaxel
1
Gemcitabine
1
Carboplatin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Recurrent Epithelial Ovarian, Fallopian or Peritoneal Carcinoma
×
90 days
×
Clear all
NCT04274426
2026-05-13
MIROVA
AGO Research GmbH
Phase 2
Active not recruiting
136 enrolled